~ 100711 Novel Methods to Cure Drug Addiction - References

References

1. Available at: http://www.whitehousedrugpolicy.gov/publications/pdf/consdrug_fs.pdf. Accessed April 29, 2011.

2. Available at: http://online.wsj.com/article/SB10001424052748704254604574614230731506644.html. Accessed April 29, 2011.

3. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final Data for 2007. National Vital Statistics Reports 58/9. Centers for Disease Control and Prevention. National Center for Health Statistics. 2010 May.

4. Available at: http://www.oas.samhsa.gov/spotlight/spotlight021counseling.pdf. Accessed April 29, 2011.

5. Available at: http://www.caron.org/current-statistics.html. Accessed April 28, 2011.

6. Available at: http://www.nida.nih.gov/podat/faqs.html. Accessed April 28, 2011.

7. Sponaugle MR. Brain Chemistry and Addiction. 2011.

8. Office of Applied Studies. Drug Abuse at Highest Level in Nearly a Decade. Rockville, MD: Department of Health and Human Services; December 2010.

9. Available at: http://www.whitehousedrugpolicy.gov/drugfact/prescrptn_drgs/rx_ff.html. Accessed April 28, 2011.

10. Available at: http://www.adolescent-substance-abuse.com/national-drug-statistics.html. Accessed April 28, 2011.

11. Available at: http://www.oas.samhsa.gov/2k10/DAWN034/EDHighlights.htm. Accessed April 28, 2011.

12. Available at: http://oas.samhsa.gov/2k10/DAWN015/IllicitAbuse.cfm. Accessed April 28, 2011.

13. Cosgrove KP. Imaging receptor changes in human drug abusers. Curr Top Behav Neurosci. 2010;3:199-217.

14. Martinez D, Narendran R. Imaging neurotransmitter release by drugs of abuse. Curr Top Behav Neurosci. 2010;3:219-45.

15. Weinstein AM. Computer and video game addiction-a comparison between game users and non-game users. Am J Drug Alcohol Abuse. 2010 Sep;36(5):268-76.

16. Blum K, Chen AL, Chen TJ, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 2008 Nov 12;5:24.

17. George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010 Nov;35(2):232-47.

18. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010 Jan;35(1):217-38.

19. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009 Sep-Oct;32(5):269-76.

20. Spooren W, Lesage A, Lavreysen H, Gasparini F, Steckler T. Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci. 2010;2:391-413.

21. Freitas-Ferrari MC, Hallak JE, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):565-80.

22. Koh KB, Kang JI, Lee JD, Lee YJ. Shared neural activity in panic disorder and undifferentiated somatoform disorder compared with healthy controls. J Clin Psychiatry. 2010 Dec;71(12):1576-81.

23. Nikolaus S, Antke C, Beu M, Muller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. Rev Neurosci. 2010;21(2):119-39.

24. Bonini JS, Da Silva WC, Da Silveira CK, Kohler CA, Izquierdo I, Cammarota M. Histamine facilitates consolidation of fear extinction. Int J Neuropsychopharmacol. 2011 Jan 7:1-9.

25. Dere E, Zlomuzica A, De Souza Silva MA, Ruocco LA, Sadile AG, Huston JP. Neuronal histamine and the interplay of memory, reinforcement and emotions. Behav Brain Res. 2010 Dec 31;215(2):209-20.

26. Zarrindast MR, Nasehi M, Khansari M, Bananej M. Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. Neurosci Lett. 2011 Feb 1;489(1):38-42.

27. Katsui R, Kuniyasu H, Matsuyoshi H, Fujii H, Nakajima Y, Takaki M. The plasticity of the defecation reflex pathway in the enteric nervous system of guinea pigs. J Smooth Muscle Res. 2009 Feb;45(1):1-13.

28. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett. 2008 Jun;29(3):287-91.

29. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009 Mar;24(1):27-53.

30. Mendoza C, Matheus N, Iceta R, Mesonero JE, Alcalde AI. Lipopolysaccharide induces alteration of serotonin transporter in human intestinal epithelial cells. Innate Immun. 2009 Aug;15(4):243-50.

31. Durant C, Christmas D, Nutt D. The pharmacology of anxiety. Curr Top Behav Neurosci. 2010;2:303-30.

32. Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol. 2008 Jan 1;75(1):266-322.

33. Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience. 2011 Mar 23.

34. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry. 2003 Aug;160(8):1522-4.

35. Frye CA, Sumida K, Dudek BC, et al. Progesterone's effects to reduce anxiety behavior of aged mice do not require actions via intracellular progestin receptors. Psychopharmacology (Berl). 2006 Jun;186(3):312-22.

36. Reddy DS, O'Malley BW, Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology. 2005 Jan;48(1):14-24.

37. Morissette M, Levesque D, Di Paolo T. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study. Mol Pharmacol. 1992 Sep;42(3):480-8.

38. Purzycki CB, Shain DH. Fungal toxins and multiple sclerosis: a compelling connection. Brain Res Bull. 2010 Apr 29;82(1-2):4-6.

39. Hiestand PC, Rausch M, Meier DP, Foster CA. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Prog Drug Res. 2008;66:361, 363-81.

40. Sotgiu S, Musumeci S, Marconi S, Gini B, Bonetti B. Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains. J Neuroimmunol. 2008 Jun 15;197(1):70-3.

41. Barone R, Sotgiu S, Musumeci S. Plasma chitotriosidase in health and pathology. Clin Lab. 2007;53(5-6):321-33.

42. Russell L, Cox DF, Larsen G, Bodwell K, Nelson CE. Incidence of molds and mycotoxins in commercial animal feed mills in seven midwestern states, 1988-1989. J Anim Sci. 1991 Jan;69(1):5-12.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.